WallStreetZenWallStreetZen

NASDAQ: IMVT
Immunovant Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IMVT

Based on 6 analysts offering 12 month price targets for Immunovant Inc

Min Forecast
$22.00-35.58%
Avg Forecast
$38.50+12.74%
Max Forecast
$50.00+46.41%

Should I buy or sell IMVT stock?

Based on 6 analysts offering ratings for Immunovant Inc.

Buy
Strong Buy
2 analysts 33.33%
Buy
2 analysts 33.33%
Hold
2 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although IMVT's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates IMVT as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their IMVT stock forecasts and price targets.

IMVT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-21
lockedlocked$00.00+00.00%2026-05-21
lockedlocked$00.00+00.00%2026-04-15
lockedlocked$00.00+00.00%2026-02-09
lockedlocked$00.00+00.00%2026-01-08
Wolfe Research
Top 15%
86
BuyUpgrades$50.00+46.50%2026-01-06

1 of 1

Forecast return on equity

Is IMVT forecast to generate an efficient return?

Company
-32.91%
Industry
85.8%
Market
169.74%
IMVT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IMVT forecast to generate an efficient return on assets?

Company
-29.32%
Industry
29.42%
IMVT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IMVT earnings per share forecast

What is IMVT's earnings per share in the next 3 years based on estimates from 17 analysts?

Avg 1 year Forecast
-$2.67
Avg 2 year Forecast
-$2.73
Avg 3 year Forecast
-$1.37

IMVT revenue forecast

What is IMVT's revenue in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$39.7M
Avg 3 year Forecast
$425.4M

IMVT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IMVT$34.13$38.50+12.80%Buy
CELC$142.53$158.43+11.15%Strong Buy
PCVX$47.39$105.00+121.57%Strong Buy
KYMR$80.61$120.33+49.28%Strong Buy
TECH$47.37$64.83+36.87%Buy
View Top Biotech Stocks

Immunovant Stock Forecast FAQ

Is Immunovant Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: IMVT) stock is to Buy IMVT stock.

Out of 6 analysts, 2 (33.33%) are recommending IMVT as a Strong Buy, 2 (33.33%) are recommending IMVT as a Buy, 2 (33.33%) are recommending IMVT as a Hold, 0 (0%) are recommending IMVT as a Sell, and 0 (0%) are recommending IMVT as a Strong Sell.

If you're new to stock investing, here's how to buy Immunovant stock.

What is IMVT's earnings growth forecast for 2027-2029?

(NASDAQ: IMVT) Immunovant's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.

Immunovant's earnings in 2026 is -$505,606,000.On average, 17 Wall Street analysts forecast IMVT's earnings for 2027 to be -$549,016,575, with the lowest IMVT earnings forecast at -$676,041,202, and the highest IMVT earnings forecast at -$474,263,598. On average, 15 Wall Street analysts forecast IMVT's earnings for 2028 to be -$560,123,787, with the lowest IMVT earnings forecast at -$772,618,516, and the highest IMVT earnings forecast at -$319,050,057.

In 2029, IMVT is forecast to generate -$280,616,228 in earnings, with the lowest earnings forecast at -$595,560,106 and the highest earnings forecast at $60,360,822.

What is IMVT's revenue growth forecast for 2027-2029?

(NASDAQ: IMVT) Immunovant's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.75%.

Immunovant's revenue in 2026 is $0.On average, 15 Wall Street analysts forecast IMVT's revenue for 2027 to be $0, with the lowest IMVT revenue forecast at $0, and the highest IMVT revenue forecast at $0. On average, 13 Wall Street analysts forecast IMVT's revenue for 2028 to be $8,154,870,183, with the lowest IMVT revenue forecast at $0, and the highest IMVT revenue forecast at $48,535,027,979.

In 2029, IMVT is forecast to generate $87,344,572,559 in revenue, with the lowest revenue forecast at $281,683,834 and the highest revenue forecast at $191,300,689,593.

What is IMVT's forecast return on assets (ROA) for 2027-2029?

(NASDAQ: IMVT) forecast ROA is -29.32%, which is lower than the forecast US Biotechnology industry average of 29.42%.

What is IMVT's Price Target?

According to 6 Wall Street analysts that have issued a 1 year IMVT price target, the average IMVT price target is $38.50, with the highest IMVT stock price forecast at $50.00 and the lowest IMVT stock price forecast at $22.00.

On average, Wall Street analysts predict that Immunovant's share price could reach $38.50 by May 21, 2027. The average Immunovant stock price prediction forecasts a potential upside of 12.8% from the current IMVT share price of $34.13.

What is IMVT's Earnings Per Share (EPS) forecast for 2027-2029?

(NASDAQ: IMVT) Immunovant's current Earnings Per Share (EPS) is -$2.77. On average, analysts forecast that IMVT's EPS will be -$2.67 for 2027, with the lowest EPS forecast at -$3.29, and the highest EPS forecast at -$2.31. On average, analysts forecast that IMVT's EPS will be -$2.73 for 2028, with the lowest EPS forecast at -$3.76, and the highest EPS forecast at -$1.55. In 2029, IMVT's EPS is forecast to hit -$1.37 (min: -$2.90, max: $0.29).

What is IMVT's forecast return on equity (ROE) for 2027-2029?

(NASDAQ: IMVT) forecast ROE is -32.91%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.